Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

38.22 +3.11 (+8.86%)
Streaming Delayed Price Updated: 2:20 PM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,748,708
Open 36.13
Bid (Size) 38.20 (500)
Ask (Size) 38.24 (200)
Prev. Close 35.11
Today's Range 35.32 - 39.07
52wk Range 7.630 - 35.39
Shares Outstanding 67,176,067
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Amylyx Pharmaceuticals Stock Skyrocketed Today ↗
GLP-1 drugs aren't just for weight loss. 
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+234.7%
+234.7%
1 Month
+119.0%
+119.0%
3 Month
+200.0%
+200.0%
6 Month
+170.5%
+170.5%
1 Year
+378.3%
+378.3%

More News

Read More
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% ↗
Via MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms ↗
Via Chartmill
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx (AMLX) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Amylyx Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗
Via MarketBeat
News headline image
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $10 Million Bet on Gold Miners ↗
Via The Motley Fool
Topics Economy
News headline image
Amylyx Stock: Why the Full Pipeline Story Matters ↗
Via MarketBeat
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus ↗
Via MarketBeat
News headline image
Amylyx (AMLX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 38.22
When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 08/19/26 02:20 PM ET
What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 2.57B
How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?
Amylyx Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.